Davion Healthcare acquires Humaskan medical technology IP for $25 million
DAVI•Davion Healthcare completed its acquisition of medical technology intellectual property from Humaskan’s four shareholders for $25 million, comprising $2.5 million in cash and 1,730,770 new ordinary shares valued at $13 each.
1. Acquisition details
The acquired assets cover WoundSkan, a battery-free wound-monitoring dressing, and Spektra, a rapid multi-marker screening platform. The acquisition includes commercialization rights but excludes Humaskan’s corporate entity, employees and liabilities.
2. Payment terms
Davion Healthcare will issue the shares on January 20, 2027, and the cash payment is due by February 19, 2027.
Related News
Xtend secures $2.35 million Middle East defense order one day after reporting nine-month revenue above full-year 2025
XTND•
Artiva Biotherapeutics expects workforce reduction completion in Q1 2027 and majority of costs in Q4 2026
ARTV•
